United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 5,410 shares of United Therapeutics stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $578.83, for a total transaction of $3,131,470.30. Following the completion of the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at $187,797,341.69. This trade represents a 1.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.
United Therapeutics Trading Down 3.2%
UTHR traded down $18.24 during trading hours on Thursday, hitting $559.10. 376,470 shares of the company’s stock were exchanged, compared to its average volume of 551,985. United Therapeutics Corporation has a 12-month low of $455.63 and a 12-month high of $614.23. The firm has a 50 day moving average of $547.74 and a 200 day moving average of $538.10. The firm has a market cap of $23.81 billion, a P/E ratio of 21.10, a price-to-earnings-growth ratio of 3.88 and a beta of 0.49.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). The business had revenue of $832.50 million for the quarter, compared to analyst estimates of $781.14 million. United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. United Therapeutics’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the company earned $7.16 earnings per share. As a group, research analysts expect that United Therapeutics Corporation will post 25.08 EPS for the current fiscal year.
United Therapeutics announced that its board has authorized a share repurchase program on Thursday, October 22nd that authorizes the company to buy back $2 billion in outstanding shares. This buyback authorization authorizes the biotechnology company to purchase up to 8.3% of its shares through open market purchases. Share buyback programs are often a sign that the company’s management believes its shares are undervalued.
Analysts Set New Price Targets
UTHR has been the subject of a number of recent research reports. BTIG Research lifted their target price on United Therapeutics from $728.00 to $768.00 and gave the company a “buy” rating in a report on Wednesday, November 4th. Weiss Ratings cut United Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, November 9th. Jefferies Financial Group restated a “buy” rating and set a $728.00 price target on shares of United Therapeutics in a report on Wednesday, October 14th. Raymond James Financial set a $720.00 price target on United Therapeutics in a research report on Wednesday, November 4th. Finally, JPMorgan Chase & Co. decreased their price objective on United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a research note on Wednesday, October 28th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $676.40.
View Our Latest Analysis on UTHR
Institutional Investors Weigh In On United Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of United Therapeutics in the 2nd quarter valued at about $2,868,735,000. Jupiter Topco LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter worth about $450,140,000. Bank of New York Mellon Corp purchased a new stake in United Therapeutics during the second quarter worth approximately $159,522,000. Caisse de depot et placement du Quebec purchased a new stake in United Therapeutics during the second quarter worth approximately $154,304,000. Finally, Legal & General Group Plc purchased a new stake in United Therapeutics during the second quarter worth approximately $112,209,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.
About United Therapeutics
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
Recommended Stories
- Five stocks we like better than United Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
